Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
NVS-MLLT-1 is an inhibitor of the YEATS domain-containing proteins MLLT1 and MLLT3 (IC50s = 0.15 and 0.254 µM, respectively).1 It is selective for MLLT1 and MLLT3 over the YEATS domain-containing proteins YEATS2 and YEATS4 (IC50s = >20 µM for both), as well as over the cat eye syndrome critical region protein 2 (CECR2) bromodomain (IC50 = >40 µM). NVS-MLLT-1 binds to wild-type MLLT1 (IC50 = 0.18 µM) and MLLT1 containing an in-frame insertion (T1 mutant) or deletion (T2 mutant) mutation (Kds = 0.24 and 0.22 µM, respectively).2 See the Structural Genomics Consortium (SGC) website for more information.
WARNING This product is not for human or veterinary use.
1. NVS-
2. Structure and inhibitor binding characterization of oncogenic MLLT1 mutants. ACS Chem. Biol. 16(4), 571-578 (2021).